StemCells Inc. (Nasdaq: STEM) is a clinical-stage biotechnology company focused on the development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. Though controversial to many people, cell-based discoveries are important in medical and scientific advances.

The company’s HuCNS-SC product candidate (purified human neutral stem cells) is undergoing clinical trials to treat retinal and spinal cord damage and will soon be showcased to neuroscientists around the globe. StemCells today announced it will present the results of its retinal degeneration and spinal cord injury research program at the Society for Neuroscience Annual Meeting later this month in Washington, D.C.

As the world’s largest organization centered on advances in understanding the brain and nervous system, The Society for Neuroscience has established this annual meeting to allow neuroscientists all around the world to present, observe and discuss scientific breakthroughs, technology and advances. StemCells has established an ongoing

...

BioHeart is a biotechnology corporation that develops devices designed to aid in the diagnosis, monitoring, and treatment of cardiovascular diseases. The company aims to improve heart disease sufferers’ quality of life, while attempting to reduce the normally exorbitant costs associated with cardiologic treatments.

In a press statement issued on Thursday, the company announced that it had received a United States Patent and Trademark Office Notice of Allowance for nine new patent claims, which pertain to using electrical signals to stimulate heart cell regeneration. BioHeart’s new technologies are a significant step forward in the field of cardiovascular treatment in that they utilize fundamental electro-chemical genetic instructions to “teach” undifferentiated stem cells to grow into heart muscle. This process will aid heart failure victims in regrowing damaged heart tissue, and could potentially save lives.

“The best way to predict the future is to create it,” said BioHeart’s director of surgical and clinical

...

Proteonomix Inc. is a biotechnology company dedicated to the development of cell therapies to treat a wide variety of diseases. Headquartered in Mountainside, New Jersey, their current research is focused on cosmetics, antiaging, and injury. Through their subsidiary ProteoDERM, INC., they are commercializing their various products.

Their new line of anti-aging skin care products is now hitting the market. Their ProteoDERM Inc.’s anti-aging products are their Matrix NC-138 system of products. They sell the Matrix NC-138™ (3%) Serum, and a Day Cream SPF-25, Night Cream, a Gentle Cleanser, and a Gentle Exfoliator.

Proteonomix is also developing a platform for the growth of contaminant-free human embryonic stem (hES) cell lines. They will then make these available to the research community. They anticipate the commercialization of this product in the fourth quarter of this year. Proteonomix is working with leading scientists at prestigious institutions around the world to make tailored stem cell

...

There are a lot of big percentage moves in broken stocks (stem cells included). It seems like people have let their guard down again and are chasing "junk stocks" higher. When we see this type of activity it is often late in a move. Do not be like the herd, RAISE your respect for risk in this environment and listen only to price.

There are a lot of big percentage moves in broken stocks (stem cells included). It seems like people have let their guard down again and are chasing "junk stocks" higher. When we see this type of activity it is often late in a move. Do not be like the herd, RAISE your respect for risk in this environment and listen only to price.

If you purchased any of the stem cell stocks I mentioned as election playsLAST THURSDAY I would recommend lightening up a bit into this strength.These stocks were also great election play when I mentioned them 2 YEARS AGO

If you purchased any of the stem cell stocks I mentioned as election playsLAST THURSDAY I would recommend lightening up a bit into this strength.These stocks were also great election play when I mentioned them 2 YEARS AGO

Cosmetic & Reconstructive Medicine Companies Outpace the Healthcare Sector The accompanying table presents the statistics and seven highest rated companies from the ETFI Global Cosmetic and Reconstructive Medicine [CRM] Index, which includes companies with market caps over $100M engaged in prescription skin care treatments, weight loss, cosmetic medicine, regenerative medicine, orthopedic repair, and joint replacements. Over the past year, the CRM Index fared better than the Healthcare Sector SPDR (XLV) and the S&P 500 SPDR (SPY) for the top 30 rated companies and all 50 companies included in the index. Top rated companies profiled in the accompanying table include CryoLife (CRY) (biomaterials & tissue repair), Valeant Pharma (VRX) (skin care), Perrigo (PRGO) (skin care), Merit Medical Systems (MMSI) (products ...

Stem Cell Therapy International Corp. (SCII.OB), which is in the process of formally changing its name to AmStem International, is on track to become one of the largest providers of cord blood stem cells in the world. AmStem, already successfully pursuing U.S. and European stem cell markets, is now positioning itself as a major player in Asia through its acquisition of Korean stem cell company HistoStem, the largest cord blood bank facility in the world (the nearest competitor is less than half as big).

HistoStem is the only company in Korea approved by the Korean FDA to provide stem cells for clinical and surgical applications. There is no comparable regulatory approval of stem cells at this level anywhere in the world. HistoStem has successfully developed a number of pioneering technologies to isolate and work with stem cells in the treatment of disease, and has an established supply chain allowing it

...

Proteonomix Inc. is a biotechnology company dedicated to the development of cell therapies to treat a wide variety of diseases. Headquartered in Mountainside, New Jersey, their current research is focused on cosmetics, anti-aging, and injury. Through their subsidiary, ProteoDERM, INC., they are commercializing their various products.

Their new line of anti-aging skin care products is now hitting the market. These anti-aging products are the Matrix NC-138 system of products, sold as Matrix NC-138™ (3%) Serum, Day Cream SPF-25, Matrix Night Cream, a gentle cleanser and a gentle exfoliator.

Proteonomix is also developing a platform for the growth of contaminant-free human embryonic stem (hES) cell lines. They will then make these available to the research community. They anticipate the commercialization of this product in the fourth quarter of this year. Proteonomix is working with leading scientists at prestigious institutions around the world to make tailored stem cell therapies a reality.

The

...